Affiliation:
1. Departments of Internal Medicine
2. Department of Pathology, Stanford University, Stanford, California 94305
3. Molecular Microbiology and Immunology, Saint Louis University, St. Louis, Missouri 63110
Abstract
ABSTRACT
Hepatitis C virus (HCV) often causes a persistent infection associated with hypergammaglobulinemia, high levels of antiviral antibody and circulating immune complexes, and immune complex disease. We previously reported that only a limited neutralizing activity to vesicular stomatitis virus or HCV pseudotype is generated in animals immunized with recombinant HCV envelope proteins and chronically infected HCV patient sera. Interestingly, when some of these neutralizing sera were diluted into a range of concentrations below those that reduced virus plaque number, an increase in pseudotype plaque formation was observed. Purified HCV E2-specific human monoclonal antibodies were used to further verify the specificity of this enhancement, and one- to twofold increases were apparent on permissive Huh-7 cells. The enhancement of HCV pseudotype titer could be inhibited by the addition of a Fc-specific anti-human immunoglobulin G Fab fragment to the virus-antibody mixture prior to infection. Treatment of cells with antibody to Fc receptor I (FcRI) or FcRII, but not FcRIII, also led to an inhibition of pseudotype titer enhancement in an additive manner. Human lymphoblastoid cell line (Raji), a poor host for HCV pseudotype infection, exhibited a four- to sixfold enhancement of pseudotype-mediated cell death upon incubation with antibody at nonneutralizing concentrations. A similar enhancement of cell culture-grown HCV infectivity by a human monoclonal antibody was also observed. Taken together, antibodies to viral epitopes enhancing HCV infection need to be taken into consideration for pathogenesis and in the development of an effective vaccine.
Publisher
American Society for Microbiology
Subject
Virology,Insect Science,Immunology,Microbiology
Reference73 articles.
1. Baré, P., I. Massud, C. Parodi, L. Belmonte, G. García, M. N. Campos, M. Corti, M. T. Pinto, R. P. Bianco, M. M. Bracco, R. Campos, and B. R. Ares. 2005. Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J. Gen. Virol.86:1717-1727.
2. Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
3. Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells
4. Boyer, V., C. Delibrias, N. Noraz, E. Fischer, M. D. Kazatchkine, and C. Desgranges. 1992. Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand. J. Immunol.36:879-883.
5. Brown, M. G., C. A. King, C. Sherren, J. S. Marshall, and R. Anderson. 2006. A dominant role for Fc RII in antibody-enhanced dengue virus infection of human mast cells and associated CCL5 release. J. Leukoc. Biol.80:242-250.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献